X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Recently published results from a Phase 1 trial conducted by ONCOtherapeutics among 28 heavily previously treated MM patients administered RUX, lenalidomide (LEN) and MP demonstrated that the therapy was well tolerated and RUX overcame refractoriness to LEN and steroids.
Lead Product(s): Ruxolitinib Phosphate,Lenalidomide,Methylprednisolone
Therapeutic Area: Oncology Product Name: Jakafi
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2022
Details:
Recently published results from a Phase 1 trial for 28 heavily previously treated MM patients administered Ruxolitinib, lenalidomide and methylprednisolone demonstrated that the therapy was well tolerated and RUX overcame refractoriness to LEN and steroids.
Lead Product(s): Ruxolitinib Phosphate,Lenalidomide,Methylprednisolone
Therapeutic Area: Oncology Product Name: Jakafi
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Incyte Corporation
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
